166 related articles for article (PubMed ID: 30032299)
41. Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?
Tefferi A; Pardanani A; Li CY
Blood; 2003 Oct; 102(8):3073-4; author reply 3074. PubMed ID: 14527892
[No Abstract] [Full Text] [Related]
42. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
43. Therapy-related acute myeloid leukemia with eosinophilia, basophilia, t(4;14)(q12;q24) and PDGFRA rearrangement: a case report and review of the literature.
Zhou J; Papenhausen P; Shao H
Int J Clin Exp Pathol; 2015; 8(5):5812-20. PubMed ID: 26191303
[TBL] [Abstract][Full Text] [Related]
44. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
45. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic complexities of eosinophilia.
Montgomery ND; Dunphy CH; Mooberry M; Laramore A; Foster MC; Park SI; Fedoriw YD
Arch Pathol Lab Med; 2013 Feb; 137(2):259-69. PubMed ID: 23368869
[TBL] [Abstract][Full Text] [Related]
47. Serum tryptase levels in pediatric mastocytosis and association with systemic symptoms.
Seth N; Tuano KT; Buheis M; Chan A; Chinen J
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):219-221. PubMed ID: 32371241
[No Abstract] [Full Text] [Related]
48. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of
Baer C; Muehlbacher V; Kern W; Haferlach C; Haferlach T
Haematologica; 2018 Aug; 103(8):e348-e350. PubMed ID: 29567772
[No Abstract] [Full Text] [Related]
49. Eosinophilic myeloid disorders.
Noel P
Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
[TBL] [Abstract][Full Text] [Related]
50. Eosinophilia in mast cell disease.
Kovalszki A; Weller PF
Immunol Allergy Clin North Am; 2014 May; 34(2):357-64. PubMed ID: 24745679
[TBL] [Abstract][Full Text] [Related]
51. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.
Klion AD; Noel P; Akin C; Law MA; Gilliland DG; Cools J; Metcalfe DD; Nutman TB
Blood; 2003 Jun; 101(12):4660-6. PubMed ID: 12676775
[TBL] [Abstract][Full Text] [Related]
52. Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis.
Bulai Livideanu C; Apoil PA; Lepage B; Eischen M; Laurent C; Laharrague P; Lamant L; Tournier E; Tavitian S; Pouplard C; Recher C; Laroche M; Mailhol C; Dubreuil P; Hermine O; Blancher A; Paul C
Clin Exp Allergy; 2016 Jan; 46(1):133-41. PubMed ID: 26767494
[TBL] [Abstract][Full Text] [Related]
53. Myelomastocytic leukemia: histopathological features, diagnostic criteria and differential diagnosis.
Horny HP; Sotlar K; Reiter A; Valent P
Expert Rev Hematol; 2014 Aug; 7(4):431-7. PubMed ID: 25025369
[TBL] [Abstract][Full Text] [Related]
54. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.
Lahortiga I; Akin C; Cools J; Wilson TM; Mentens N; Arthur DC; Maric I; Noel P; Kocabas C; Marynen P; Lessin LS; Wlodarska I; Robyn J; Metcalfe DD
Haematologica; 2008 Jan; 93(1):49-56. PubMed ID: 18166785
[TBL] [Abstract][Full Text] [Related]
55. [Hypereosinophilia as the leading symptom in a patient with mastocytosis].
Musch E; Parwaresch R; Malek M; Chrissafidou A
Med Klin (Munich); 2005 May; 100(5):286-7. PubMed ID: 15902384
[No Abstract] [Full Text] [Related]
56. Contemporary Classification and Diagnostic Evaluation of Hypereosinophilia.
Mattis DM; Wang SA; Lu CM
Am J Clin Pathol; 2020 Aug; 154(3):305-318. PubMed ID: 32525541
[TBL] [Abstract][Full Text] [Related]
57. [Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia].
Qu SQ; Qin TJ; Xu ZF; Zhang Y; Jia YJ; Ai XF; Zhang HL; Fang LW; Hu NB; Pan LJ; Li B; Liu JQ; Ru K; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):501-506. PubMed ID: 30032569
[No Abstract] [Full Text] [Related]
58. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.
Tefferi A; Pardanani A
Int J Hematol; 2004 Jun; 79(5):441-7. PubMed ID: 15239393
[TBL] [Abstract][Full Text] [Related]
59. [Cytogenetic study on eosinophilia].
Zhang Y; He Q; Huang XJ; Jiang H; Yang SM; Lu J; Qing YZ; Shi Y; Dang H; Qiu JY; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):454-7. PubMed ID: 17605843
[TBL] [Abstract][Full Text] [Related]
60. Eosinophilia: secondary, clonal and idiopathic.
Tefferi A; Patnaik MM; Pardanani A
Br J Haematol; 2006 Jun; 133(5):468-92. PubMed ID: 16681635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
